Hanyang Securities reported on HLB that “Hengrui Medicine of China and HLB are preparing for further global clinical trials of 'Camrelizumab' + 'Rivoceranib'” and added, “HLB's market cap of 4 Trillion KRW is a relatively attractive price”. As such, Hanyang suggested a stock purchase and set a target price of 144,000 KRW.

Researcher Oh Byung-Yong judged, "The more joint clinical trials are conducted, the more global investors will compare the market cap of Hengrui Medicine and HLB." He also pointed out that “there is a lot of money coming into the domestic stock market, but it is difficult to find a business that can be improved under the influence of COVID-19” and emphasized, “It's time to pay attention to HLB as the market’s supply and demand is comparatively low and is looking for bio stocks with the momentum.”